BioMarin Pharmaceutical | BMRN - Loan Capital


BioMarin Pharmaceutical reported $596.66M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Bayer EUR 32.71B 1B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
Insmed USD 539.72M 21.23M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Moderna USD 26M 6M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 1.84B 298.68M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025